The role of adipocytokines in the hormonal regulation of insulin resistance
https://doi.org/10.34680/2076-8052.2021.3(124).21-26
Abstract
The role of adipocytokines in the hormonal regulation of insulin resistance is topical due to the wide spread of insulin resistance, which is recorded in 100% of cases of overweight and 80% of insulin-dependent diabetes mellitus, on the one hand, and its stressor pathology, on the other. It was found that when combined with type 2 diabetes mellitus with dyslipidemia, hyperuricemia, and hypertension, the incidence of insulin resistance increases to 95%. Also, the development of insulin resistance contributes to chronic neuropsychic and physical stress, the effect of unfavorable environmental factors that lead to hormonal and metabolic changes aimed at increasing energy education in order to ensure adaptive processes. Disorders of glucose metabolism in the liver are associated with a change in the spectrum of bioregulators at atherogenic type, increased hyperglycemia and hyperlipidemia. Adipocytokines play an important role in the functioning of adipose tissue in normal and pathological conditions, since inflammation is involved in the regulation of food needs and supports the homeostasis of adipose tissue. The new scientific knowledge on the regulation of adipocytocon metabolism in the development of insulin resistance opens the possibility of developing a method of preventing and correcting metabolic disorders by controlling the content of adipocytokines.
About the Authors
O. M. Balaeva-Tikhomirova
Витебский государственный университет им. П.М. Машерова
Belarus
Belarus
E. I. Katsnelson
Витебский государственный университет им. П.М. Машерова
Belarus
Belarus
A. S. Volodko
Витебский государственный университет им. П.М. Машерова
Belarus
Belarus
N. S. Fomicheva
Витебский государственный университет им. П.М. Машерова
Belarus
Belarus
N. N. Maksimyuk
Новгородский государственный университет имени Ярослава Мудрого
Russian Federation
Russian Federation
L. A. Moskvina
Новгородский государственный университет имени Ярослава Мудрого
Russian Federation
Russian Federation
References
1. Litvinova L.S., Kirienkova E.V., Mazunin I.O. et al. Patogenez insulinorezistentnosti pri metabolicheskom ozhirenii [Pathogenesis of insulin resistance in metabolic obesity]. Biomeditsinskaya khimiya, 2015, vol.61, pp.70-82.
2. Rasin M.S. Vospalenie i insulinorezistentnost' kak ob"ekty profilaktiki i terapii nealkogol'noy zhirovoy bolezni pecheni [Inflammation and insulin resistance as objects of prevention and therapy of non-alcoholic fatty liver disease]. Suchasna gastroenterologiya, 2015, no.3 (83), pp.105-112.
3. Jequier E. Leptin signaling, adiposity, and energy balance. Ann. N. Y. Acad. Sci., 2002, vol.967, pp.379-388.
4. Novitskii A.A., Aleksanin S.S., Dudarenko S.V Mekhanizm razvitiya patologii vnutrennikh organov v usloviyakh ekologicheskogo i professional'nogo perenapryazheniya regulyatornykh sistem organizma cheloveka [The mechanism of development of pathology of internal organs in the conditions of ecological and professional overstrain of regulatory systems of the human body]. Medico-Biological and SocioPsychological Problems of Safety in Emergency Situations, 2010, no.1, pp.5-9.
5. Hotamisligil G.S., Erbay E. Nutrient sensing and inflammation in metabolic diseases. Nat. Rev. Immunol., 2008, vol.8, pp.923-934.
6. Pal'tsev M.A., Kvetnoy I.M., Il'nitskiy A.N. et al. Ozhirenie: molekulyarnye mekhanizmy i optimizatsiya targetnoy terapii [Adiposity: molecular mechanisms and optimization of targeted therapy]. Molekulyarnaya meditsina, 2013, no.2, pp.3- 12.
7. Yamakado M. et al. Clinical study on the role of leptin and insulin resistance in the pathogenesis of obesity-related hypertension. Am. J. Hyperten., 2001, vol.14, pp.222A.
8. Shigemura N., Ohta R., Kusakabe Y., et al. Leptin modulates behavioral responses to sweet substances by influencing peripheral taste structures. Endocrin., 2004, vol.145, pp.839-847.
9. Gorreria M.L., Morgan D.A., Sivitz W. I., et al. Leptin acts in the central nervous system to produce dose-dependent changes in arterial pressure. Hypertension, 2001, vol.37, pp.936-942.
10. Torpy D.J., Bornstein S.R., Cizza G., et al. The effects of glucocorticoids on leptin levels in humans may be restricted to acute pharmacologic dosing. J. Clin. Endocrinol. Metab., 1998, vol.83, pp.1821-1822.
11. Kotz C.M., Briggs J., Grace M., et al. Divergence of the feeding and thermogenic pathways influenced by NPY in the hypothalamic PVN of the rats. Amer. J. Physiol., 1998, vol.275, pp.471-477.
12. Szanto I., Kahn C. Selective interaction between leptin and insulin signaling pathways in a hepatic cell line. Proc. Natl. Acad. Sci. USA, 2000, vol.97, pp.2355-2360.
13. Kim Y.B., Uotani Sh., Pierroz D.D., et al. In vivo administration of leptin activates signal transduction directly in insulin-sensitive tissues: overlapping but distinct pathways from insulin. Endocrin., 2000, vol.141, pp.2328-2339.
14. Gullicksen P.S., Della-Fera M.A., Baile C.A. Leptin-induced adipose apoptosis: implications for body weight regulation. Apoptosis, 2003, vol.8, pp.327-335.
15. Unger R.H., Orci L. Diseases of liporegulation: new perspective on obesity and related disorders. FASEB J., 2001, vol.15, pp.312-321.
16. Rahmouni K., Haynes W.G., Morgan D.A., et al. Selective resistance to central neural administration of leptin in Agouti obese mice. Hypertension, 2002, vol.39, pp.486-490.
17. Ozata M., Dieguez C., Casanueva F.F. The inhibition of growth hormone secretion presented in obesity is not mediated by the high leptin levels: a study in human leptindeficiencypatients. J. Clin. Endocrinol. Metab., 2003, vol.88, pp.312-316.
18. Lord G.M., Matarese G., Howard J.K., et al. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature, 1998, vol.394, pp. 897-901.
19. Britov A.N., Molchanova O.V., Bystrova M.M. Vzaimosvyaz' urovnya leptina s gemodinamicheskimi pokazatelyami i postprandial'noy glikemiey u patsientov s ozhireniem i arterial'noy gipertoniey [The correlation of leptin levels with hemodynamic indicators and the postprandial glycemia in patients with obesity and hypertension]. Kardiovask. ter. i prof., 2004, vol.3, no.2, pp. 27-30.
20. Mamedov M.N. et al. Tkanevaya insulinorezistentnost': stepen' vyrazheniya i vzaimosvyaz' s faktorami riska serdechno-sosudistykh zabolevaniy [Tissue insulin resistance: the degree of expression and the relationship with risk factors of cardiovascular diseases]. Ros. kardiol. Zhurn., 2000, no.1, pp.44-47.
21. Hauner H., Bender M., Haastert B., et al. Plasma concentration of TNF-α and its soluble receptors in obese subjects. Int. J. Obes. Relat. Metah. Disord., 1998, vol.22, pp.1239-1243.
22. Voiarova V., Weyer C., Hanson K., et al. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes. Res., 2001, vol. 9, pp.414-417.
23. Gustafson B., Hammarstedt A., Andersson C.X., et al. Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 2007, vol.27, pp.2276-2283.
24. Danilova L.I., Murashko N.V. Metabolicheskiy sindrom [Metabolic syndrome]. Proceedings of the National Academy of Sciences of Belarus, Medical series, 2004, no.1, pp.10-14.
25. Taranushenko T.E., Oorzhak U.S., Salminа A.B., et al. Narushenie uglevodnogo obmena i insulinorezistentnost' pri ozhirenii u detey [Violation of carbohydrate metabolism and insulin resistance in obesity in children]. Endokrinologiya, 2017, pp.37-45.
26. Arner E., Rydén M., Arner P., et al. Tumor Necrosis Factor and Regulation of Adipose Tissue. N. Engl. J. Med., 2010, vol.362, pp.1151-1153.
27. Novitskiy A.A. Metabolicheskiy sindrom (sindrom Kh) – «bolezn' tsivilizatsii» / [Metabolic syndrome (syndrome X) – “disease of civilization”]. Donozologiya, 2008, no.2(3), pp.15-19.
28. Chandron M., Phillips S.A., Ciaraldi T., et al. Adiponectin: more then just another fat cell hormone? Diabetes Care, 2003, vol.26, pp.2442-2450.
29. Kubota N., Terauchi Y., Yamauchi T., et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J. Biol. Chem., 2002, vol.277, pp.25863-25866.
30. Matsuzawa Y. Adipocytokines and metabolic syndrome. Semin. Vasc. Med., 2005, vol.5, no.1, pp.34-39.
31. Lihn A., Østergård T., Nyholm B., et al. Adiponectin expression in adipose tissue is reduced in first-degree relatives of type 2 diabetic patients. Am. J. Physiol. Endocrinol. Metab., 2003, vol. 284, p.E443–E448.
32. Yamauchi T., Kamon J., Waki H., et al. Globular adiponectin protected ob/ob mice from diabetes and apoE-deficient mice from atherosclerosis. J. Biol. Chem., 2003, v.278, p.2461-2468.
33. Matsuiawa Y., Funahashi T., Kihara S., et al. Adiponectin and metabolic syndrome. Arterioscler. Thromb. Vase Biol., 2004, vol.24, pp.29-33.
34. Matsubara M., Maruoka Sh., Katayose Sh., et al. Decreased plasma adiponectin concentrations in women with dyslipidemia. J. Clin. Endocrinol. Metab., 2002, vol.87, pp.2764-2769.
35. Frolova Yu.V. Rol' aktivnosti lipoproteinlipazy, giperinsulinemii i urovnya neesterifitsirovannykh zhirnykh kislot v razvitii dislipidemiy [The role of lipoprotein lipase activity, hyperinsulinemia and the level of non-esterified fatty acids in the development of dyslipidemia]. Med. akadem. zhurn., 2005, no.5, pp.43-49.
36. Starkova N.T. et al. Metabolicheskiy sindrom insulinorezistentnosti: osnovnaya kontseptsiya i sledstvie [Metabolic syndrome of insulin resistance: the main concept and consequence]. Terapevtich. Arkhiv, 2004, no.10, p.54-58.
37. Tanyanskiy D.A. et al. Adeponektin: snizhenie soderzhaniya pri metabolicheskom sindrome i nezavisimaya svyaz' s gipertriglitseridemiey [Adeponectin: a decrease in the content of metabolic syndrome and an independent relationship with hypertriglyceridemia]. Kardiologiya, 2008, no.12, pp.20-25.
38. Yamauchi T., Kamon J., Minokoshi Y., et al. Adiponectin stimulatesglucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med., 2002, vol.8, no.11, pp.288-295.
39. Yokota T., Oritani K., Takahashi I., et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood, 2000, vol. 96, pp.1723-1732.
40. Bruun J., Lihn A.S., Verdich C., et al. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am. J. Physiol. Endocrinol. Metab., 2003, vol.285, pp.E527–E533.
41. Balaeva-Tikhomirova O.M. Gormonal'no-metabolicheskie vzaimosvyazi pri razvitii sindroma insulinorezistentnosti: monografiya [Hormonal-metabolic relationships in the development of insulin resistance syndrome: monograph]. Vitebsk, VGU imeni P.M. Masherova Publ., 2013, 177 p.
42. Ametov A.S. Insulinosekretsiya i insulinorezistentnost': dve storony odnoy medali [Insulinosecretion and insulin resistance: two sides of the same coin]. Problemy endokrinologii, 2002, vol.48, no.3, pp.31-36.
43. Balabolkin M.I., Dedov I.I. Geneticheskie aspekty sakharnogo diabeta [Genetic aspects of diabetes]. Sakharnyy diabet, 2000, no.1, pp.2-10.
44. Matsubara M., Katayose S., Maruoka S., et al. Decreased plasma adiponectin concentrations in nondiabetic women with elevated homeostasis model assessment ratios. Eur. J. Endocrinol., 2003, vol.148, pp.343-350.
45. Shuldiner A.,Yang R., Gong D.W. Resistin, obesity and insulin resistance. N. Engl. J. Med., 2001, vol.345, no.18, pp.1345-1346.
46. Chernysh O.V., Mokhort T.V. Bazal'nyy uroven' tsitokinov pri metabolicheskom sindrome [Basal cytokine level in metabolic syndrome]. Zdravookhranenie, 2007, no.3, pp.4-6.
47. Ogonov R.G., Aleksandrov A.A. Giperinsulinemiya i arterial'naya gipertoniya: vozvrashchayas' k vyvodam United Kingdom Prospective Diabetes Study [Hyperinsulinemia and hypertension: insights returning to the United Kingdom Prospective Diabetes Study]. Rus. med. Zhurn., 2002, no.1, pp.486-491.
48. Smith W. Resistin – resistant to define their roles. O. B. E. s. Res., 2002, vol.10, pp.61-62.
Review
For citations:
Balaeva-Tikhomirova O.M., Katsnelson E.I., Volodko A.S., Fomicheva N.S., Maksimyuk N.N., Moskvina L.A. The role of adipocytokines in the hormonal regulation of insulin resistance. Title in english. 2021;(3(124)):21-26. (In Russ.) https://doi.org/10.34680/2076-8052.2021.3(124).21-26
Views:
36
Email this article 